An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC).

被引：0
|
作者：
Dirix, L.
Canon, J. L.
Amadori, D.
Villa, E.
Aldrighetti, D.
Machiels, J. P.
Verkh, L.
Bouko, Y.
Kem, K.
Giorgetti, C.
Cardoso, F.
机构：
[1] AZ ST Augustinus, Antwerp, Belgium
[2] Grand Hop Charleroi, Charleroi, Belgium
[3] IRST, Meldola, Italy
[4] San Raffaele, Milan, Italy
[5] Univ Catholique Louvain, B-1200 Brussels, Belgium
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, Milan, Italy
[8] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：852S / 853S
页数：2
相关论文
共 50 条
  • [1] Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer
    Cardoso, F.
    Canon, J. L.
    Amadori, D.
    Dirix, L.
    Villa, E.
    Aldrighetti, D.
    Machiels, J. P.
    Verkh, L.
    Kern, K.
    Giorgetti, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 283 - 283
  • [2] Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer
    Cardoso, F.
    Canon, J-L
    Amadori, D.
    Dirix, L.
    Villa, E.
    Aldrighetti, D.
    Machiels, J-P
    Verkh, L.
    Huang, X.
    Giorgetti, C.
    CANCER RESEARCH, 2009, 69 (02) : 286S - 287S
  • [3] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [4] Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)
    Bergh, J.
    Greil, R.
    Voytko, N.
    Makhson, A.
    Cortes, J.
    Lortholary, A.
    Huang, X.
    Giorgetti, C.
    Kern, K. A.
    Lichinitser, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [5] Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation
    Mariani, G.
    Cardoso, F.
    Besse-Hammer, T.
    Vigano, L.
    Liljegren, A.
    Verkh, L.
    Huang, X.
    Giorgetti, C.
    Bergh, J.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
    Kozloff, M.
    Chuang, E.
    Starr, A.
    Gowland, P. A.
    Cataruozolo, P. E.
    Collier, M.
    Verkh, L.
    Huang, X.
    Kern, K. A.
    Miller, K.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1436 - 1441
  • [7] Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: Overall survival results from BOLERO-1
    Yardley, D.
    Hurvitz, S.
    Jiang, Z-F
    Toi, M.
    Burris, H.
    Buyse, M.
    Slamon, D.
    Makhson, A.
    Elsaid, A.
    Lerzo, G.
    Hellerstedt, B.
    Nuzzo, F.
    Sohn, J.
    Manzyuk, L.
    Cabaribere, D.
    Lincy, J.
    Weimann, A.
    Noel-Baron, F.
    Pacaud, L.
    Andre, F.
    CANCER RESEARCH, 2017, 77
  • [8] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [9] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
  • [10] A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2.
    Polyzos, A
    Mavroudis, D
    Boukovinas, J
    Tsiakopoulos, E
    Malamos, N
    Milaki, G
    Kouroussis, C
    Kotsakis, A
    Pallis, A
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 59S - 59S
12345